medigraphic.com
ISSN 1665-3254 (Print)
Revista Oficial de la Universidad Biomédica Rafael Guízar y Valencia A. C.

2005, Number 1-2

<< Back Next >>

Plasticidad y Restauración Neurológica 2005; 4 (1-2)

New indications of the botulinum toxin type A (BTA)

Aguilar-Rebolledo F

Language: Spanish
References: 13
Page: 25-30
PDF size: 186.38 Kb.


ABSTRACT

The disorders discussed here for which botulinum neurotoxin therapies are emerging treatments represent only a portion of the novel applications of these treatments that have been reported in the literature. Botulinum toxin type A has been found to improve sialorrhea, hyperhidrosis, and pain with few side effects. Ultimately, these compounds are useful because they inhibit acetylcholine release following local injection, a property that may be capitalized upon in the treatment of many different focal disorders in which reduced cholinergic tone is desired. This basic property point out botulinum toxin A is a outstanding a medication for novel uses in the future.


REFERENCES

  1. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type A treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49(1):34-8.

  2. Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med Hypotheses 1997;48(4) :337-9.

  3. Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 2003;61(4):454-7.

  4. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54(1):244-7.

  5. Racette BA, Good L, Sagitto S, Perlrnutter JS. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord 2003;18(9):1059-61.

  6. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomized, panallel group, double blind, placebo controlled trial. BMJ 2001;15:596-9.

  7. Cruccu G et al. EFNS Guidelines on neuropathy pain assessment. European Journal of Neurology 2004;11:153-62.

  8. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003;43(8):853-60.

  9. Silberstein S, Mathew N, Saper J, Jenkins S. BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40(6):445-50.

  10. Aguilar-Rebolledo F, Hernandez SJ, Rayo MD, Soriano FF, Garcia MLI, Ruiz PJ et al. Botulinum toxin as a treatment for spasticity and dystonia in pediatric cerebral palsy. Gac Med Mex 2001;137: 403-11.

  11. Aguilar-Rebolledo F, Pascual-Pascual P. Tratamiento de la espasticidad. Toxina botulínica. Plast & Rest Neurol 2003;2:23-32.

  12. Aguilar-Rebolledo F. Toxina botulínica tipo A TBA en la Espasticidad en el nińo. Plast & Rest Neurol 2004;3:78-84.

  13. Aguilar-Rebolledo F, Hernández- Sánchez J. Toxina botulínica TBA en el manejo del dolor. Cirug & Ciruj 2005. (En revisión).




2020     |     www.medigraphic.com